Publications by authors named "Catherine A Shu"

Claim this Profile
A
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, Susanna Cheng, Shun Lu, Joshua K Sabari, Catherine A Shu

Target Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Institution Analysis of Tarlatamab for the Treatment of -Mutant Transformed Small Cell Lung Cancer.
Alissa J Cooper, Benjamin Herzberg, Mitchell Parma, Kaiwen Wang, Laura Alder, Catherine A Shu

JCO Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, Ji-Youn Han, Ki Hyeong Lee, Catherine A Shu, Joshua C Curtin

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis.
Jay M Lee, Alessandro Brunelli, Amy L Cummings, Enriqueta Felip, Catherine A Shu

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer.
Lanyi Nora Chen, Xin Ma, Benjamin Herzberg, Brian S Henick, Anup K Biswas, Catherine A Shu

Oncologist· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLC.
Margaux Wooster, Michael May, Prashasti Agrawal, Jonathan Lee, Benjamin May, Catherine A Shu

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E Marmarelis, Catherine A Shu, Joshua C Curtin, Joshua M Bauml

J Thorac Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late Metastases.
Michelle Garlin Politis, Mahesh Mansukhani, Benjamin O Herzberg, Lanyi N Chen, Mark Stoopler, Joshua Sonett, Catherine A Shu

J Pers Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases.
Somnath Tagore, Lindsay Caprio, Amit Dipak Amin, Kresimir Bestak, Karan Luthria, Catherine A Shu

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Catherine A Shu

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn, Catherine A Shu, Joshua Sabari

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deconstructing the Monolith: An Educational Module for Understanding Disparities Within Asian American, Native Hawaiian, and Pacific Islander Populations.
Karan D Luthria, Dylan K Kim, Samantha Xing, Mina Yuan, Jerry Zhou, Catherine A Shu

MedEdPORTAL· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.
Brian S Henick, Peter D Koch, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Joshua R Sonett, Catherine A Shu

J Immunother Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Catherine A Shu

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From and Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
Luke R G Pike, Emily Miao, Lillian A Boe, Tejas Patil, Brandon S Imber, Joshua D Palmer, Catherine A Shu

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.
Shahnaz Singh-Kandah, Kaiwen Wang, Karen Xia, Andy Lain Johnson, Denise M D'Andrea, Catherine A Shu

Clin J Oncol Nurs· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unusual presentation of rearranged metastatic non-small cell lung cancer.
Lanyi Nora Chen, Claire Keating, Jay Leb, Anjali Saqi, Catherine A Shu

Respir Med Case Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
Kaiwen Wang, Robyn Du, Nathaniel J Myall, Whitney E Lewis, Natalie Uy, Catherine A Shu

J Thorac Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case study on severe psychiatric symptoms induced by lorlatinib.
Michael A Liu, Eleanor Xu, Catherine A Shu

Psychooncology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Shu-Chi Tseng, Catherine A Shu

Cancer Discov· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Prabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Catherine A Shu

Cancer Discov· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
Dong-Wan Kim, Sang-We Kim, D Ross Camidge, Catherine A Shu, Kristen A Marrone

J Thorac Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Keunchil Park, Joshua K Sabari, Eric B Haura, Catherine A Shu, Alexander Spira, Joshua M Bauml, Joshua C Curtin

Lung Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
Lanyi Nora Chen, Alexander Z Wei, Catherine A Shu

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.
Rohan Maniar, Stephanie M Gallitano, Sameera Husain, Golnaz Moazami, Michael J Weiss, Catherine A Shu

J Natl Compr Canc Netw· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis